NEW YORK – BillionToOne said on Thursday that it has signed an exclusive distribution agreement with Eluthia to launch BillionToOne's Unity noninvasive prenatal test in certain European countries.
Eluthia, based in Heidelberg, Germany, will offer Unity in Germany, Austria, Switzerland, and the Netherlands.
Unity enables screening for the autosomal recessive conditions cystic fibrosis, spinal muscular atrophy, sickle cell disease, and other hemoglobinopathies from fetal DNA gathered from maternal blood. The assay uses BillionToOne's proprietary quantitative counting template method, which eliminates the amplification bias that can hamper accurate quantification and counting of DNA molecules of interest in a blood sample.
With the new agreement, Unity will be available outside the US for the first time, said Menlo Park, California-based BillionToOne.
"With Eluthia's genetic testing and regulatory experience and their extensive physician network in Central Europe, we are confident that the Unity test will dramatically improve the standard of prenatal care in Europe," BillionToOne Founder and CEO Oguzhan Atay said in a statement.
BillionToOne closed an oversubscribed $15 million Series A financing round in March.